Dulaglutide is associated with a delay in gastric emptying, which may influence the of orally administered medications.
A population pharmacokinetic model estimated that dulaglutide's effect on gastric emptying is dose-dependent.
The modeling approach was able to reproduce observed interactions between dulaglutide and other drugs at low doses.
At a dose of 1.5 mg, dulaglutide showed no clinically relevant impact on the pharmacokinetics of small molecules.
Predictions for drug-drug interactions were made for a 4.5 mg dose of dulaglutide, indicating similar outcomes.
The findings suggest that modeling can enhance the understanding of potential drug interactions related to gastric emptying.
Simplified
Dulaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, is approved for improving glycemic control and reducing cardiovascular risks in patients with type 2 diabetes mellitus (T2DM). This research investigates the effect of dulaglutide on gastric emptying and its impact on the (PK) of orally administered molecules utilizing a combination of population pharmacokinetic (PopPK) and physiologically based pharmacokinetic (PBPK) modeling approaches. In clinical studies, the (GED) was evaluated in healthy participants and patients with T2DM at various dose levels of dulaglutide. A PopPK model estimated the exposure-dependent delay in gastric emptying, which was then input into the orally administered small molecule PBPK models. These PBPK models, informed by internal clinical studies and publicly available data, quantified the effect of dulaglutide-induced GED on the area under the curve (AUC), maximum concentration (C), and time to maximum concentration (t) of the co-administered drugs. The modeling approach was verified for reproducing observed GED-mediated drug-drug interactions (DDIs) at low doses of dulaglutide and to predict DDIs at a 4.5 mg dulaglutide dose. The clinical studies demonstrated that the 1.5 mg dulaglutide dose has no clinically relevant effect on the pharmacokinetics of small molecules, and the modeling led to a similar conclusion at 4.5 mg dulaglutide. This work demonstrates that modeling approaches can be used to predict potential GLP-1-mediated DDIs related to gastric emptying delay, increasing the efficiency of the clinical pharmacology programs. max max
Key numbers
5.66 h
Gastric Mean Residence Time
Mean residence time for gastric emptying after 4.5 mg dulaglutide.
0.93 (0.86, 1.00)
AUC Ratio for Acetaminophen
AUC ratio when co-administered with 4.5 mg dulaglutide.
Full Text
We can’t show the full text here under this license.
All authors (M.M.P., K.B.S., B.L.M., B.T., J.F.R., L.R.A.R., L.S.T., S.D.H., S.D.S., and G.L.D.) are paid employees or retirees of Eli Lilly and Company and hold stock ownership in Eli Lilly and Company.
